BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Eisai Inc. (ESALF.PK) Insurer Balks at Paying Whistleblower Claim


11/26/2012 8:11:51 AM

For the past several years, nearly every large drugmaker has agreed to pay settlements with the US federal government over allegations of illegal promotions. Generally, these deals result from separate, but related lawsuits filed by former employees who claim they were fired in retaliation for complaining about alleged off-label marketing practices. Taken together, the growing number of settlements have resulted in multi-billion payments to federal and state governments, as well as separate payments to former employees. Yet critics say these sums are regarded as a cost of doing business when the drugs involved ring the register at a much higher rate over an extended period of time. But what happens when an insurer balks at paying a claim? Suddenly, the cost might seem real. This is what Eisai executives are facing. The drugmaker, which is based in Japan but has US offices in New Jersey, is now suing Zurich American Insurance for refusing to pay a claim concerning a whistleblower lawsuit filed by a former sales rep. The underlying details follow a familiar pattern. In this case, Michael Keeler was a sales rep in Florida who balked at alleged Eisai managerial efforts to promote the Ontak cancer treatment for unapproved uses. After complaining that compensation was wrongfully tied to such promotions, he was eventually terminated, according to his lawsuit.

Read at Pharmalot


Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->